

# Percentage of Public Drug Program Spending on Generic Drugs

Name	Percentage of Public Drug Program Spending on Generic Drugs
Short/Other Names	Not applicable
Description	The rate of public drug program spending on generic drugs
Interpretation	This indicator is interpreted as the proportion of public drug program spending for generic drug products.
HSP Framework Dimension	Health System Inputs and Characteristics: Efficient allocation of resources
Areas of Need	Not applicable
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia, Yukon
Reporting Level/Disaggregation	Province/Territory
Indicator Results	<a href="https://secure.cihi.ca/estore/productSeries.htm?locale=en&amp;pc=PCC1011">https://secure.cihi.ca/estore/productSeries.htm?locale=en&amp;pc=PCC1011</a>

## Identifying Information

Name	Percentage of Public Drug Program Spending on Generic Drugs
Short/Other Names	Not applicable
Indicator Description and Calculation	
Description	The rate of public drug program spending on generic drugs Total public drug program spending on generic drugs divided by total public drug program spending
Calculation: Description	Unit of Analysis: Spending from public drug programs Place of residence Percentage or proportion None Not applicable
Calculation: Geographic Assignment	
Calculation: Type of Measurement	
Calculation: Adjustment Applied	
Calculation: Method of Adjustment	
Denominator	<b>Description:</b> Total public drug program spending <b>Inclusions:</b> All claims accepted by public drug programs <b>Exclusions:</b> Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket <b>Description:</b> Total public drug program spending on generic drug products <b>Inclusions:</b> All claims for generic drugs accepted by public drug programs <b>Exclusions:</b> 1. Any claims not submitted to or accepted by public drug programs, including claims submitted to a private insurer or cases where the individual pays out of pocket 2. Claims for brand name products
Numerator	
Background, Interpretation and Benchmarks	
Rationale	This indicator measures the proportion of public drug program spending that generic drugs account for.
Interpretation	This indicator is interpreted as the proportion of public drug program spending for generic drug products.
HSP Framework Dimension	Health System Inputs and Characteristics: Efficient allocation of resources
Areas of Need	Not applicable
Targets/Benchmarks	Not applicable
References	Not applicable
Availability of Data Sources and Results	
Data Sources	NPDUIS Database <b>Type of Year:</b> Calendar <b>First Available Year:</b>

Available Data Years

	2000
	<b>Last Available Year:</b>
	2017
Geographic Coverage	Newfoundland and Labrador, Prince Edward Island, New Brunswick, Nova Scotia, Quebec, Ontario, Manitoba, Saskatchewan, Alberta, British Columbia, Yukon
Reporting Level/Disaggregation	Province/Territory
Result Updates	
Update Frequency	Whenever required for analytical product or data request
Indicator Results	<b>Web Tool:</b> <i>Prescribed Drug Spending in Canada</i> <b>URL:</b> <a href="https://secure.cihi.ca/estore/productSeries.htm?locale=en&amp;pc=PCC1011">https://secure.cihi.ca/estore/productSeries.htm?locale=en&amp;pc=PCC1011</a>
Updates	Not applicable
Quality Statement	– Includes only drugs claimed through public drug programs
Caveats and Limitations	– Excludes any drugs claimed through a private drug plan or purchased over the counter All data is not available for all years: – Manitoba, Saskatchewan, Alberta, New Brunswick: From January 2000 – Nova Scotia: From April 2001 – Prince Edward Island: From April 2004 – British Columbia: From January 2006 – Yukon: From January 2007 – Newfoundland and Labrador: From April 2008 – Ontario: From April 2010 – First Nations and Inuit Health Branch: From October 2010
Trending Issues	Not applicable
Comments	